vanoxerine has been researched along with Tachycardia, Ventricular in 1 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 9.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| "Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF)." | 5.22 | Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. ( Camm, AJ; Cotter, G; Davison, BA; Dittrich, HC; Feld, G; Iwashita, J; Koch, G; Kowey, PR; Piccini, JP; Pritchett, EL; van Gelder, IC; Waldo, A; Wiener, LE, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piccini, JP | 1 |
| Pritchett, EL | 1 |
| Davison, BA | 1 |
| Cotter, G | 1 |
| Wiener, LE | 1 |
| Koch, G | 1 |
| Feld, G | 1 |
| Waldo, A | 1 |
| van Gelder, IC | 1 |
| Camm, AJ | 1 |
| Kowey, PR | 1 |
| Iwashita, J | 1 |
| Dittrich, HC | 1 |
1 trial available for vanoxerine and Tachycardia, Ventricular
| Article | Year |
|---|---|
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR.
Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blin | 2016 |